Who are target treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ibrance, Abemaciclib + Fulvestrant, Palbociclib, Palbociclib in combination with AI, Abemaciclib + Aromatase Inhibitor, Palbociclib PD-0332991.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/target-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

target treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

target treatment (target treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor. Area: Oncology.

marketed CDK4/6 inhibitor CDK4/6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

target treatment (target treatment) — Institut Bergonié. This drug targets the CDK4/6 pathway to inhibit cancer cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
target treatment TARGET	target treatment	Institut Bergonié	marketed	CDK4/6 inhibitor	CDK4/6
Ibrance	Palbociclib	Pfizer	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)	2015-01-01
Abemaciclib + Fulvestrant	Abemaciclib + Fulvestrant	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + estrogen receptor antagonist	CDK4/6 and estrogen receptor (ER)
Palbociclib	palbociclib	Pfizer Inc.	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)
Palbociclib in combination with AI	palbociclib-in-combination-with-ai	Pfizer	marketed	CDK inhibitor	CDK4/6
Abemaciclib + Aromatase Inhibitor	Abemaciclib + Aromatase Inhibitor	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + Aromatase inhibitor combination	CDK4/6 + Aromatase
Palbociclib PD-0332991	Palbociclib PD-0332991	GBG Forschungs GmbH	phase 3	CDK4/6 inhibitor	CDK4/6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor class)

AstraZeneca · 1 drug in this class
Centre Leon Berard · 1 drug in this class
Draig Therapeutics Ltd · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
GBG Forschungs GmbH · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Institut Bergonié · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Kartos Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). target treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/target-treatment. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing